BioCentury on BioBusiness,
Table: Follow-on performance
Back to the parent article
Monday, July 1, 2013
The biotech industry raised $4.2 billion via 33
follow-on deals in 2Q13 - the third largest quarterly amount raised for this
offering type since BioCentury started tracking the industry's financings in
1994. The $5.2 billion raised in 4Q00 was the largest, followed by the $4.3
billion raised in 1Q00. Excluding the $2.3 billion follow-on by Valeant
Pharmaceuticals International Inc. (TSX:VRX; NYSE:VRX) to fund the
acquisition of Bausch + Lomb Inc., the remaining 32 offerings in 2Q13
come in at $1.9 billion, still ahead of the $1.1 billion raised via 23 deals in
The 2Q13 follow-on class is up a median of 2%, with
the percentage changes
words displayed of
To read this article, you must be an Archives subscriber. Please choose one of the options below.
All contents Copyright © 1993-2017 BioCentury Publications, Inc. ALL RIGHTS RESERVED. All use of this Web Site and its contents is governed by the BioCentury User Agreement
. The contents of this Web Site are protected under U.S. and foreign copyright and intellectual property laws, and no part of this Web Site or its contents may be photocopied, reproduced or retransmitted in any form without the written consent of BioCentury, which may be requested from Reprints/Permissions
. BioCentury®; The Bernstein Report on BioBusiness™; The BioCentury 100™; The Clear Route to ROI™; Because Real Intelligence is Hard to Find™; BCIQ™; and BioPharma's Knowledge Center™; are trademarks of BioCentury Publications, Inc., P.O. Box 1246, San Carlos, CA 94070. SciBX® and SciBX: Science-Business eXchange® are trademarks of Nature America, Inc. that are jointly used by BioCentury Publications, Inc. and Nature America, Inc.
Whether you want an individual subscription or need a global group license, we have the products,
the experience and the customer support that biopharma executives, researchers, investors, service providers,
and industry stakeholders have trusted for nearly two decades.
Let our Subscriber Services team customize the best intelligence package available in the industry to meet your needs.
Free Trial Subscription 4 Weeks of Access
BioCentury's Weekly Business Intelligence Journal
Get a 4-week free trial subscription to BioCentury.
Get 4 Weeks Free
Thanks for purchasing this article.
Please bookmark this url for future reference.
We have also sent you a confirming e-mail with a receipt and this same url for your
close [ X ]